Oxaliplatin-induced neuropathy in colorectal cancer

Journal of Oncology

Volumn , Issue , 2011, Pages

  Weickhardt, Andrew ^a   Wells, Keith ^a   Messersmith, Wells ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA3 INTEGRIN; CARBAMAZEPINE; GABAPENTIN; GLUCONATE CALCIUM; GLUTAMINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; LAMOTRIGINE; MAGNESIUM SULFATE; OXALIPLATIN; OXCARBAZEPINE; PREGABALIN; THIOCTIC ACID; VENLAFAXINE; XALIPRODEN;

AGE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DRUG INDUCED DISEASE; DYSESTHESIA; FASCICULATION; FOLLOW UP; GENETIC DIFFERENCE; HAND PARESTHESIA; HUMAN; HYPERACTIVITY; JAW DISEASE; MUSCLE CRAMP; NAUSEA; NEUROPATHY; NEUROTOXICITY; OXIDATIVE STRESS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TUMOR VOLUME;

EID: 84855570246     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2011/201593     Document Type: Review

References (61)

1. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., De Gramont A., Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer New England Journal of Medicine 2004 350 23 2343 2351 (Pubitemid 38702845)
2. Schmoll H. J., Cartwright T., Tabernero J., Nowacki M. P., Figer A., Maroun J., Price T., Lim R., Van Cutsem E., Park Y. S., McKendrick J., Topham C., Soler-Gonzalez G., De Braud F., Hill M., Sirzén F., Haller D. G., Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients Journal of Clinical Oncology 2007 25 1 102 109 (Pubitemid 350003057)
3. Masi G., Vasile E., Loupakis F., Cupini S., Fornaro L., Baldi G., Salvatore L., Cremolini C., Stasi I., Brunetti I., Fabbri M. A., Puglisi M., Trenta P., Granetto C., Chiara S., Fioretto L., Allegrini G., Crin L., Andreuccetti M., Falcone A., Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis Journal of the National Cancer Institute 2011 103 1 21 30
4. Alcindor T., Beauger N., Oxaliplatin: a review in the era of molecularly targeted therapy Current Oncology 2011 18 1 18 25
5. Chaney S. G., Raymond E., Faivre S., Woynarowski J. M., Oxaliplatin: mechanism of action and antineoplastic activity Seminars in Oncology 1998 25 2 4 12 (Pubitemid 28248696)
6. Hartmann J. T., Lipp H. P., Toxicity of platinum compounds Expert Opinion on Pharmacotherapy 2003 4 6 889 901 (Pubitemid 36722480)
7. Cersosimo R. J., Oxaliplatin-associated neuropathy: a review Annals of Pharmacotherapy 2005 39 1 128 135 (Pubitemid 40052388)
8. Argyriou A. A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H. P., A review on oxaliplatin-induced peripheral nerve damage Cancer Treatment Reviews 2008 34 4 368 377
9. Adelsberger H., Quasthoff S., Grosskreutz J., Lepier A., Eckel F., Lersch C., The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons European Journal of Pharmacology 2000 406 1 25 32
10. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., Gamelin E., A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels Journal of Neurophysiology 2001 85 5 2293 2297 (Pubitemid 32440704)
11. Gamelin L., Capitain O., Morel A., Dumont A., Traore S., Anne L. B., Gilles S., Boisdron-Celle M., Gamelin E., Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway Clinical Cancer Research 2007 13 21 6359 6368 (Pubitemid 350075025)
12. Grothey A., Clinical management of oxaliplatin-associated neurotoxicity Clinical Colorectal Cancer 2005 5 1, supplement 1 S38 S46
13. Services, U.S.D.o.H.a.H.,. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010
14. Cornblath D. R., Chaudhry V., Carter K., Lee D., Seysedadr M., Miernicki M., Joh T., Total neuropathy score: validation and reliability study Neurology 1999 53 8 1660 1664 (Pubitemid 29530336)
15. Cavaletti G., Bogliun G., Marzorati L., Zincone A., Piatti M., Colombo N., Parma G., Lissoni A., Fei F., Cundari S., Zanna C., Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale Neurology 2003 61 9 1297 1300 (Pubitemid 37377562)
16. Cassidy J., Clarke S., Daz-Rubio E., Scheithauer W., Figer A., Wong R., Koski S., Lichinitser M., Yang T. S., Rivera F., Couture F., Sirzén F., Saltz L., Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer Journal of Clinical Oncology 2008 26 12 2006 2012
17. Falcone A., Ricci S., Brunetti I., Pfanner E., Allegrine G., Barbara C., Crin L., Benedetti G., Evangelista W., Fanchini L., Cortesi E., Picene V., Vitello S., Chiara S., Granetto C., Porcile G., Fioretto L., Orlandini C., Andreuccetti M., Masi G., Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nord ovest Journal of Clinical Oncology 2007 25 13 1670 1676 (Pubitemid 46797946)
18. Grothey A., Nikcevich D. A., Sloan J. A., Kugler J. W., Silberstein P. T., Dentchev T., Wender D. B., Novotny P. J., Chitaley U., Alberts S. R., Loprinzi C. L., Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7 Journal of Clinical Oncology 2011 29 4 421 427
19. Allegra C. J., Yothers G., O'Connell M. J., Sharif S., Colangelo L. H., Lopa S. H., Petrelli N. J., Goldberg R. M., Atkins J. N., Seay T. E., Fehrenbacher L., O'Reilly S., Chu L., Azar C. A., Wolmark N., Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer Journal of Clinical Oncology 2009 27 20 3385 3390
20. De Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., De Braud F., Wilson C., Morvan F., Bonetti A., Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer Journal of Clinical Oncology 2000 18 16 2938 2947 (Pubitemid 30644117)
21. Land S. R., Kopec J. A., Cecchini R. S., Ganz P. A., Wieand H. S., Colangelo L. H., Murphy K., Kuebler J. P., Seay T. E., Needles B. M., Bearden J. D., Colman L. K., Lanier K. S., Pajon E. R., Cella D., Smith R. E., O'Connell M. J., Costantino J. P., Wolmark N., Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07 Journal of Clinical Oncology 2007 25 16 2205 2211 (Pubitemid 46954644)
22. Argyriou A. A., Polychronopoulos P., Iconomou G., Koutras A., Makatsoris T., Gerolymos M. K., Gourzis P., Assimakopoulos K., Kalofonos H. P., Chroni E., Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer Acta Oncologica 2007 46 8 1131 1137 (Pubitemid 350058888)
23. Park S. B., Lin C. S.Y., Krishnan A. V., Goldstein D., Friedlander M. L., Kiernan M. C., Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility Oncologist 2011 16 5 708 716
24. Ramanathan R. K., Rothenberg M. L., de Gramont A., Tournigand C., Goldberg R. M., Gupta S., André T., Incidence and evolution of oxaliplatin-induced eripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies Annals of Oncology 2009 21 4 754 758
25. Goldberg R. M., Tabah-Fisch I., Bleiberg H., De Gramont A., Tournigand C., Andre T., Rothenberg M. L., Green E., Sargent D. J., Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer Journal of Clinical Oncology 2006 24 25 4085 4091 (Pubitemid 46622283)
26. Adler V., Yin Z., Fuchs S. Y., Benezra M., Rosario L., Tew K. D., Pincus M. R., Sardana M., Henderson C. J., Wolf C. R., Davis R. J., Ronai Z., Regulation of JNK signaling by GSTp EMBO Journal 1999 18 5 1321 1334 (Pubitemid 29110316)
27. Elsby R., Kitteringham N. R., Goldring C. E., Lovatt C. A., Chamberlain M., Henderson C. J., Wolf C. R., Park B. K., Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi Journal of Biological Chemistry 2003 278 25 22243 22249 (Pubitemid 36830271)
28. Henderson C. J., McLaren A. W., Moffat G. J., Bacon E. J., Wolf C. R., Pi-class glutathione S-transferase: regulation and function Chemico-Biological Interactions 1998 111-112 69 82 (Pubitemid 28271935)
29. Lecomte T., Landi B., Beaune P., Laurent-Puig P., Loriot M. A., Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy Clinical Cancer Research 2006 12 10 3050 3056 (Pubitemid 43837350)
30. Kanai M., Yoshioka A., Tanaka S., Nagayama S., Matsumoto S., Nishimura T., Niimi M., Teramukai S., Takahashi R., Mori Y., Kitano T., Ishiguro H., Yanagihara K., Chiba T., Fukushima M., Matsuda F., Associations between glutathione S-transferase Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy Cancer Epidemiology 2010 34 2 189 193
31. Antonacopoulou A. G., Argyriou A. A., Scopa C. D., Kottorou A., Kominea A., Peroukides S., Kalofonos H. P., Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? European Journal of Neurology 2010 17 7 963 968
32. Lee S., Won H., Son E., Genetic polymorphism associated with chronic neurotoxicity and recurrence in curatively-resected colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy Journal of Clinical Oncology 28 15, supplement 3583. ASCO Meeting Abstracts, 2010
33. Tournigand C., Cervantes A., Figer A., Lledo G., Flesch M., Buyse M., Mineur L., Carola E., Etienne P. L., Rivera F., Chirivella I., Perez-Staub N., Louvet C., André T., Tabah-Fisch I., De Gramont A., OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancera GERCOR study Journal of Clinical Oncology 2006 24 3 394 400 (Pubitemid 46630458)
34. Hochster H. S., Grothey A., Childs B. H., Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity Journal of Clinical Oncology 2007 25 25 4028 4029 (Pubitemid 47477294)
35. Grothey A., Hart L. L., Rowland K. M., Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial Journal of Clinical Oncology 26 15, supplement 4010. ASCO Meeting Abstracts, 2008
36. Chau I., Cunningham D., Treatment in advanced colorectal cancer: what, when and how? British Journal of Cancer 2009 100 11 1704 1719
37. Chibaudel B., Maindrault-Goebel F., Lledo G., Mineur L., André T., Bennamoun M., Mabro M., Artru P., Carola E., Flesch M., Dupuis O., Colin P., Larsen A. K., Afchain P., Tournigand C., Louvet C., De Gramont A., Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study Journal of Clinical Oncology 2009 27 34 5727 5733
38. Tabernero J., Aranda E., Gomez A., Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]) Journal of Clinical Oncology 28 15, supplement 3501. ASCO Meeting Abstracts, 2010
39. Gamelin E., Gamelin L., Bossi L., Quasthoff S., Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures Seminars in Oncology 2002 29 5, supplement 15 21 33 (Pubitemid 35191038)
40. Gamelin L., Boisdron-Celle M., Delva R., Guérin-Meyer V., Ifrah N., Morel A., Gamelin E., Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer Clinical Cancer Research 2004 10 12 4055 4061 (Pubitemid 38812481)
41. Knijn N., Tol J., Koopman M., Werter M. J. B. P., Imholz A. L. T., Valster F. A. A., Mol L., Vincent A. D., Teerenstra S., Punt C. J. A., The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients European Journal of Cancer 2010 47 3 369 374
42. Gamelin L., Boisdron-Celle M., Morel A., Poirier A. L., Berger V., Gamelin E., Tournigand C., De Gramont A., Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy Journal of Clinical Oncology 2008 26 7 1188 1189
43. Cascinu S., Catalano V., Cordella L., Labianca R., Giordani P., Baldelli A. M., Beretta G. D., Ubiali E., Catalano G., Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial Journal of Clinical Oncology 2002 20 16 3478 3483
44. Lin P. C., Lee M. Y., Wang W. S., Yen C. C., Chao T. C., Hsiao L. T., Yang M. H., Chen P. M., Lin K. P., Chiou T. J., N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data Supportive Care in Cancer 2006 14 5 484 487
45. Wang W. S., Lin J. K., Lin T. C., Chen W. S., Jiang J. K., Wang H. S., Chiou T. J., Liu J. H., Yen C. C., Chen P. M., Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients Oncologist 2007 12 3 312 319
46. Lu P., Fan Q. X., Wang L. X., Wang X., Zong H., Wang R. L., Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors Ai Zheng 2008 27 10 1117 1120
47. Guo Y., Palmer J. L., Forman A., A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic acid to prevent platinum-induced polyneuropathy Journal of Clinical Oncology 29 15, supplement 9010. ASCO Meeting Abstracts, 2011
48. von Delius S., Eckel F., Wagenpfeil S., Mayr M., Stock K., Kullmann F., Obermeier F., Erdmann J., Schmelz R., Quasthoff S., Adelsberger H., Bredenkamp R., Schmid R. M., Lersch C., Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study Investigational New Drugs 2007 25 2 173 180 (Pubitemid 46020877)
49. Argyriou A. A., Chroni E., Polychronopoulos P., Iconomou G., Koutras A., Makatsoris T., Gerolymos M. K., Gourzis P., Assimakopoulos K., Kalofonos H. P., Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy Neurology 2006 67 12 2253 2255 (Pubitemid 46035491)
50. Mitchell P. L., Goldstein D., Michael M., Beale P., Friedlander M., Zalcberg J., White S., Thomson J. A., Calrke S., Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity Clinical Colorectal Cancer 2006 6 2 146 151 (Pubitemid 44445750)
51. Durand J. P., Brezault C., Goldwasser F., Protection against oxaliplatin acute neurosensory toxicity by venlafaxine Anti-Cancer Drugs 2003 14 6 423 425 (Pubitemid 36951792)
52. Rao R. D., Flynn P. J., Sloan J. A., Wong G. Y., Novotny P., Johnson D. B., Gross H. M., Renno S. I., Nashawaty M., Loprinzi C. L., Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3 Cancer 2008 112 12 2802 2808 (Pubitemid 351969227)
53. Park S. B., Goldstein D., Lin C. S.-Y., Krishnan A. V., Friedlander M. L., Kiernan M. C., Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment? Journal of Clinical Oncology 2011 29 18 e553 e554
54. Reynolds A., Laurie C., Lee Mosley R., Gendelman H. E., Oxidative stress and the pathogenesis of neurodegenerative disorders International Review of Neurobiology 2007 82 297 325
55. Holmes J., Stanko J., Varchenko M., Hong H., Madden V. J., Bagnell C. R., Wyrick S. D., Chaney S. G., Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a wistar rat model Toxicological Sciences 1998 46 2 342 351 (Pubitemid 29069619)
56. Appert-Collin A., Duong F. H. T., Passilly Degrace P., Warter J. M., Poindron P., Gies J. P., MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden International Journal of Immunopathology and Pharmacology 2005 18 1 21 31 (Pubitemid 40343456)
57. Cassidy J., Bjarnason G. A., Hickish T., Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) Journal of Clinical Oncology 2006 24 18, supplement 3507
58. Durand J. P., Deplanque G., Montheil V., Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology. In press
59. Kautio A. L., Haanp M., Saarto T., Kalso E., Amitriptyline in the Treatment of Chemotherapy-Induced Neuropathic Symptoms Journal of Pain and Symptom Management 2008 35 1 31 39 (Pubitemid 350299098)
60. Mariani G., Garonne O., Granetto C., Oxaliplatin induced neuropathy: could gabapentin be the answer? Journal of Clinical Oncology 19 19, supplement 2937. ASCO Meeting Abstracts, 2000
61. Saif M. W., Hashmi S., Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer Cancer Chemotherapy and Pharmacology 2008 61 3 349 354 (Pubitemid 350275990)